MX393076B - Uso de derivados de ribósido de ácido nicotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores que incrementan nad+ - Google Patents
Uso de derivados de ribósido de ácido nicotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores que incrementan nad+Info
- Publication number
- MX393076B MX393076B MX2018012849A MX2018012849A MX393076B MX 393076 B MX393076 B MX 393076B MX 2018012849 A MX2018012849 A MX 2018012849A MX 2018012849 A MX2018012849 A MX 2018012849A MX 393076 B MX393076 B MX 393076B
- Authority
- MX
- Mexico
- Prior art keywords
- derivatives
- riboside
- nicotinic acid
- nicotinamide
- ribofuranosyl
- Prior art date
Links
- PUEDDPCUCPRQNY-ZYUZMQFOSA-N D-ribosylnicotinate Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1[N+]1=CC=CC(C([O-])=O)=C1 PUEDDPCUCPRQNY-ZYUZMQFOSA-N 0.000 title abstract 3
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 title abstract 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 title abstract 2
- 235000020956 nicotinamide riboside Nutrition 0.000 title abstract 2
- 239000011618 nicotinamide riboside Substances 0.000 title abstract 2
- 239000002243 precursor Substances 0.000 title 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 abstract 4
- IPXBSAHANXBVMU-OTVLKRCQSA-N 1-[(2R,3R,4R,5R)-3,4-diacetyl-3,4-dihydroxy-5-(1-hydroxy-2-oxopropyl)oxolan-2-yl]-2H-pyridine-3-carboxamide Chemical compound C(C)(=O)[C@@]1([C@@H](O[C@@H]([C@]1(O)C(C)=O)C(O)C(C)=O)N1CC(C(=O)N)=CC=C1)O IPXBSAHANXBVMU-OTVLKRCQSA-N 0.000 abstract 1
- QGZHUIXTGFZHJT-OTVLKRCQSA-N 1-[(2R,3R,4R,5R)-3,4-diacetyl-3,4-dihydroxy-5-(1-hydroxy-2-oxopropyl)oxolan-2-yl]-4H-pyridine-3-carboxamide Chemical compound C(C)(=O)[C@@]1([C@@H](O[C@@H]([C@]1(O)C(C)=O)C(O)C(C)=O)N1C=C(C(=O)N)CC=C1)O QGZHUIXTGFZHJT-OTVLKRCQSA-N 0.000 abstract 1
- JJICLWRQGDROCF-OTVLKRCQSA-N 1-[(2R,3R,4R,5R)-3,4-diacetyl-3,4-dihydroxy-5-(1-hydroxy-2-oxopropyl)oxolan-2-yl]-4H-pyridine-3-carboxylic acid Chemical compound C(C)(=O)[C@@]1([C@@H](O[C@@H]([C@]1(O)C(C)=O)C(O)C(C)=O)N1C=C(C(=O)O)CC=C1)O JJICLWRQGDROCF-OTVLKRCQSA-N 0.000 abstract 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 abstract 1
- 235000013361 beverage Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 230000037041 intracellular level Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229950006238 nadide Drugs 0.000 abstract 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 abstract 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 abstract 1
- 239000011664 nicotinic acid Substances 0.000 abstract 1
- 229960003512 nicotinic acid Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325264P | 2016-04-20 | 2016-04-20 | |
| PCT/US2017/028673 WO2017184885A1 (en) | 2016-04-20 | 2017-04-20 | Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018012849A MX2018012849A (es) | 2019-08-29 |
| MX393076B true MX393076B (es) | 2025-03-24 |
Family
ID=60088650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012849A MX393076B (es) | 2016-04-20 | 2017-04-20 | Uso de derivados de ribósido de ácido nicotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores que incrementan nad+ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10183036B2 (OSRAM) |
| EP (1) | EP3445359B8 (OSRAM) |
| JP (3) | JP7089480B2 (OSRAM) |
| KR (1) | KR20190008246A (OSRAM) |
| CN (1) | CN109640984A (OSRAM) |
| AU (2) | AU2017254657A1 (OSRAM) |
| BR (1) | BR112018071573A2 (OSRAM) |
| CA (1) | CA3021571C (OSRAM) |
| ES (1) | ES2948968T3 (OSRAM) |
| MX (1) | MX393076B (OSRAM) |
| NZ (1) | NZ747693A (OSRAM) |
| WO (1) | WO2017184885A1 (OSRAM) |
| ZA (1) | ZA201807736B (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3322419B1 (en) | 2015-07-15 | 2025-09-03 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
| MX2018001363A (es) | 2015-08-05 | 2018-11-29 | Metro Int Biotech Llc | Derivados del mononucleotido de nicotinamida y sus usos. |
| GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
| US10689411B2 (en) | 2016-11-11 | 2020-06-23 | The Queen's University Of Belfast | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
| MX2019006278A (es) | 2016-11-29 | 2019-08-21 | Univ Iowa Res Found | Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia. |
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| WO2018191771A1 (en) * | 2017-04-18 | 2018-10-25 | Victor Chang Cardiac Research Institute | Detection and treatment of congenital malformations |
| US11286274B2 (en) | 2017-06-19 | 2022-03-29 | Mitopower Llc | Nicotinamide riboside derivatives and their uses |
| WO2019152416A1 (en) * | 2018-01-30 | 2019-08-08 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
| EP3797110A1 (en) * | 2018-05-22 | 2021-03-31 | Jumpstart Fertility Pty Ltd | Amino acid salts of nicotinic acid ribosides as anti-aging agents |
| EP3897666A2 (en) | 2018-12-17 | 2021-10-27 | Mitopower LLC | Nicotinyl riboside compounds and their uses |
| MX2021010043A (es) | 2019-02-21 | 2022-07-19 | Chromadex Inc | Uso de nicotinamida ribósido, ácido nicotinico ribósido, compuestos de nicotinil ribósido reducido y derivados de compuestos de nicotinil ribósido en formulaciones. |
| US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
| JP7610531B2 (ja) * | 2019-06-05 | 2025-01-08 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 腎疾患を治療又は予防するための還元型ニコチンアミドリボシド |
| JP2022534872A (ja) * | 2019-06-05 | 2022-08-04 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 肝疾患の治療のための還元型ニコチンアミドリボシド |
| BR112021021690A2 (pt) * | 2019-06-05 | 2022-02-15 | Nestle Sa | Ribosídeos de nicotinamida reduzidos para tratamento/prevenção de doenças do músculo esquelético |
| CN110973260A (zh) * | 2019-12-11 | 2020-04-10 | 杨力 | 一种含有烟酰胺核糖苷的牛奶及其制备方法与应用 |
| US20230000888A1 (en) | 2019-12-19 | 2023-01-05 | Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) | Nad-precursors and dietary restriction for treating age related medical conditions |
| US20230119002A1 (en) * | 2020-03-09 | 2023-04-20 | Societe Des Produits Nestle S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions |
| WO2021180741A1 (en) * | 2020-03-09 | 2021-09-16 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions |
| JP2023517835A (ja) * | 2020-03-09 | 2023-04-27 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | ウイルス感染症及び細菌感染症の予防及び治療のために還元型ニコチンアミドリボシドを含有する組成物及び方法 |
| US20230114280A1 (en) * | 2020-03-09 | 2023-04-13 | Societe Des Produits Nestle S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions |
| CN114561342B (zh) * | 2020-11-27 | 2024-12-20 | 西安交通大学医学院第一附属医院 | Nad信号通路激动剂在体外胚胎培养中的应用 |
| CN112716969B (zh) * | 2021-01-15 | 2022-11-29 | 江苏恒正合生命科学有限公司 | 治疗阿尔茨海默症的组合物及其制备方法、应用 |
| EP4333858A2 (en) * | 2021-05-05 | 2024-03-13 | Société des Produits Nestlé S.A. | Composition and methods using combination of narh and nr to produce intracellular nicotinamide adenine dinucleotide (nad+) |
| WO2022251491A1 (en) | 2021-05-27 | 2022-12-01 | Metro International Biotech, Llc | Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use |
| EP4313067A4 (en) * | 2021-06-18 | 2024-12-18 | Mitopower LLC | TREATMENT OF IMMUNITY-RELATED DISORDERS, RENAL DISORDERS, LIVER DISORDERS, HEMOLYTIC DISORDERS AND OXIDATIVE STRESS-RELATED DISORDERS USING NRH, NARH AND THEIR REDUCED DERIVATIVES |
| JP7111878B1 (ja) | 2021-10-27 | 2022-08-02 | 旭化成ファーマ株式会社 | ニコチンアミドモノヌクレオチドの製造方法 |
| WO2023076804A1 (en) * | 2021-10-27 | 2023-05-04 | Elysium Health Inc. | Methods for treatment of menopausal syndromes |
| WO2023150072A1 (en) | 2022-02-01 | 2023-08-10 | Sinclair David A | Compositions and methods for the preservation of plant matter |
| EP4472993A2 (en) * | 2022-02-04 | 2024-12-11 | Elysium Health, Inc. | Ribose linkers and conjugates thereof |
| WO2024118503A1 (en) | 2022-11-28 | 2024-06-06 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7022680B2 (en) * | 2002-05-30 | 2006-04-04 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US7927859B2 (en) * | 2003-08-22 | 2011-04-19 | Rice University | High molar succinate yield bacteria by increasing the intracellular NADH availability |
| EP1723227A4 (en) | 2004-02-10 | 2007-09-19 | Dartmouth College | NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE |
| AU2005257883A1 (en) | 2004-06-04 | 2006-01-05 | Washington University | Methods and compositions for treating neuropathies |
| DK1957086T3 (en) * | 2005-11-18 | 2018-06-06 | Cornell Res Foundation Inc | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE |
| GB201313465D0 (en) | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
| CN105873937A (zh) * | 2013-10-30 | 2016-08-17 | 可劳迈戴斯有限公司 | 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物 |
| BR112016028672A2 (pt) * | 2014-06-06 | 2017-08-22 | Glaxosmithkline Ip No 2 Ltd | análogos de ribosídeo de nicotinamida e composições farmacêuticas e usos do mesmo |
| MX390185B (es) * | 2015-03-16 | 2025-03-20 | Chromadex Inc | Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso. |
| EP3322419B1 (en) | 2015-07-15 | 2025-09-03 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
| MX2018001363A (es) | 2015-08-05 | 2018-11-29 | Metro Int Biotech Llc | Derivados del mononucleotido de nicotinamida y sus usos. |
| AU2017248818B2 (en) * | 2016-04-14 | 2023-01-12 | ChromaDex Inc. | Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula |
-
2017
- 2017-04-20 KR KR1020187033413A patent/KR20190008246A/ko not_active Ceased
- 2017-04-20 ES ES17786649T patent/ES2948968T3/es active Active
- 2017-04-20 MX MX2018012849A patent/MX393076B/es unknown
- 2017-04-20 EP EP17786649.8A patent/EP3445359B8/en active Active
- 2017-04-20 NZ NZ747693A patent/NZ747693A/en unknown
- 2017-04-20 CN CN201780038245.5A patent/CN109640984A/zh active Pending
- 2017-04-20 AU AU2017254657A patent/AU2017254657A1/en not_active Abandoned
- 2017-04-20 US US15/492,952 patent/US10183036B2/en active Active
- 2017-04-20 BR BR112018071573-5A patent/BR112018071573A2/pt not_active Application Discontinuation
- 2017-04-20 WO PCT/US2017/028673 patent/WO2017184885A1/en not_active Ceased
- 2017-04-20 CA CA3021571A patent/CA3021571C/en active Active
- 2017-04-20 JP JP2018554765A patent/JP7089480B2/ja active Active
-
2018
- 2018-11-16 ZA ZA2018/07736A patent/ZA201807736B/en unknown
-
2021
- 2021-07-16 JP JP2021117648A patent/JP2021176871A/ja active Pending
-
2022
- 2022-08-22 AU AU2022221384A patent/AU2022221384C1/en active Active
- 2022-10-19 JP JP2022167877A patent/JP7493007B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3021571C (en) | 2023-01-03 |
| JP7493007B2 (ja) | 2024-05-30 |
| AU2022221384B2 (en) | 2023-03-23 |
| US10183036B2 (en) | 2019-01-22 |
| JP7089480B2 (ja) | 2022-06-22 |
| EP3445359C0 (en) | 2023-06-07 |
| US20170304338A1 (en) | 2017-10-26 |
| CA3021571A1 (en) | 2017-10-26 |
| KR20190008246A (ko) | 2019-01-23 |
| JP2021176871A (ja) | 2021-11-11 |
| EP3445359B1 (en) | 2023-06-07 |
| WO2017184885A1 (en) | 2017-10-26 |
| ES2948968T3 (es) | 2023-09-22 |
| JP2019514874A (ja) | 2019-06-06 |
| CN109640984A (zh) | 2019-04-16 |
| AU2022221384C1 (en) | 2023-08-03 |
| BR112018071573A2 (pt) | 2019-02-12 |
| ZA201807736B (en) | 2020-05-27 |
| MX2018012849A (es) | 2019-08-29 |
| AU2022221384A1 (en) | 2022-09-22 |
| EP3445359A1 (en) | 2019-02-27 |
| AU2017254657A1 (en) | 2018-11-15 |
| EP3445359A4 (en) | 2019-12-25 |
| WO2017184885A8 (en) | 2023-08-24 |
| EP3445359B8 (en) | 2023-09-06 |
| NZ747693A (en) | 2023-07-28 |
| JP2023002685A (ja) | 2023-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX393076B (es) | Uso de derivados de ribósido de ácido nicotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores que incrementan nad+ | |
| BR112017019696A2 (pt) | composto e usos de um composto | |
| EA201890435A1 (ru) | Производные никотинамидмононуклеотида и их применение | |
| WO2020131578A3 (en) | Nicotinyl riboside compounds and their uses | |
| MX2021009652A (es) | Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel. | |
| BR112012020742A2 (pt) | derivados de pirazolo piperidina como inibidores de nadph oxidase. | |
| MX2015005949A (es) | Nucleosidos que contienen aza-azucar antiviral. | |
| ZA201605979B (en) | 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication | |
| BR112012030818A2 (pt) | "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv" | |
| PH12014501134A1 (en) | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| MY189761A (en) | Quinazoline derivatives used to treat hiv | |
| MX352927B (es) | Derivados de 1h-pirrolo [2,3-b] piridina y su uso como inhibidores de quinasa. | |
| MX361652B (es) | Análogos de cortistatina y síntesis y usos de los mismos. | |
| CO6781467A2 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| BR112014002245A2 (pt) | derivados de piridin-2(1h)-ona como inibidores de jak | |
| MA37385B1 (fr) | Inhibiteurs de diacylglycérol-acyltransférase 2 | |
| DOP2010000342A (es) | Compuestos conteniendo nitrogeno triciclico y sus usos como antibacteriales | |
| AU2017356887A8 (en) | sGC stimulators | |
| ITTO20060239A1 (it) | Formulazione per somministrazione orale con effetti salutistici sull'apparato cardiovascolare | |
| MX2012007896A (es) | Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica. | |
| BR112016005509A8 (pt) | método de preparação de um extrato de sementes de urucum (anato), composição, extrato vegetal, e composição farmacêutica | |
| UY34009A (es) | ?uso de receptor de a2b adenosina para tratar la insuficiencia cardíaca y la arritmia en pacientes posinfarto de miocardio?. | |
| BR112015023078A2 (pt) | inibidores de pirrolopirimindina cdk9 quinase | |
| BR112018004244A2 (pt) | formulações sólidas de pirofosfato férrico solúvel, kits e seus métodos de uso | |
| PH12015501643B1 (en) | Methods of use of phenoxypropylamine compounds to treat depression |